Follow Regeneron to never miss an important update.
The European Commission approved a new dosing schedule for Libtayo, a drug used to treat skin, lung, and cervical cancers. Patients can now move to a double dose every six weeks instead of every three, and the time it takes to receive the medicine through an infusion can be cut in half to 15 minutes.
This is a practical win for the company's oncology business. Making a treatment more convenient for patients and clinics helps protect its market share against rivals. While Libtayo is smaller than the company's massive eye and immunology drugs, these updates make it a more competitive option for doctors in the European market.
Source: GlobeNewsWire
Regeneron shared data from a Phase 2 trial for its drug baloncibart, which targets POTS, a condition where a person's heart rate jumps sharply when they stand up. The trial showed that a single dose helped lower that heart rate response and improved symptoms for four weeks. This is a first-in-class treatment, meaning it works through a biological mechanism that no other drug currently uses.
While this is still in the middle stages of testing, it is a notable development because there are currently no treatments for POTS approved by the FDA. If successful in later trials, this would give Regeneron a foothold in a market with no direct competition, further diversifying its business beyond its core eye and skin treatments.
Source: GlobeNewsWire
Regeneron shared data from a study of its experimental treatment for a common liver disease known as MASLD, where fat builds up in the liver and can cause scarring. A single dose of the drug, which works by silencing a specific gene, reduced liver fat by up to 80 percent and kept it low for 36 weeks.
While this is early-stage data, it is an important win for the company's genetics-based research platform. This drug targets a different mechanism than the popular weight-loss drugs currently on the market, potentially giving the company a unique way to treat metabolic diseases if future trials are successful.
Source: GlobeNewsWire
After Regeneron reported its October results, we updated our fair value and raised our quality score to 4.6. We moved our rating from Buy to Watch. We added the impact of the fully repaid development balance to our profit projections and started tracking the newly initiated cash dividend. We also raised our sales expectations for the cancer drug Libtayo and the high dose version of Eylea.
Regeneron reported a highly successful quarter with earnings of $20.07 per share, well above the $16.42 analysts expected. Revenue grew 36 percent to about $5.1 billion. This growth was fueled by record sales of its three most important products: Dupixent for skin and lung conditions, Eylea HD for eye disease, and Libtayo for cancer. The stock rose about 12 percent following the report.
Beyond the sales numbers, the company signed a major new deal with its long-time partner Sanofi. Regeneron will receive $1 billion upfront to develop new long-acting treatments for immune system disorders, with the potential for $7 billion more if the drugs hit certain milestones. This helps solve the company's biggest challenge: proving it can keep inventing new blockbusters to replace its older medicines as their patents expire.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Management consistently sets a bar they can clear, but the recent massive jump in profit shows the business is now outrunning even their own high expectations.
| Expectation | |
|---|---|
| EPS | $25.80 |
| Revenue | $5.85B |